Oncology Venture granted IDE approval in pursuit of phase III study with LiPlaCis DRP

Oncology Venture have received an IDE approval from the FDA to use DRP for patient selection in a phase III study with the company’s drug candidate LiPlaCis. This is a huge step forward in Oncology Venture’s push to market with LiPlaCis DRP. Oncology Venture, based in Denmark, specialise in precision oncology thanks to their flagship […].